12:00 AM
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tivozanib: Phase II started

Aveo and Astellas began the double-blind, crossover, international Phase II TAURUS trial to compare 1.5 mg oral tivozanib daily for 3 consecutive weeks of a 4-week cycle for 12 weeks vs. 50 mg oral Sutent daily for 4 consecutive weeks of a 6-week cycle for 12 weeks in...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >